ORANGE BIOMED UNVEILS WORLD’S FIRST MICROFLUIDIC-BASED A1C TEST AT THE DIABETES TECHNOLOGY MEETING’S STARTUP SHOWCASE

Orange Biomed has been chosen by the Diabetes Technology Society (DTS) to present our groundbreaking research at the Diabetes Technology Meeting’s Startup Showcase, where we will unveil the OBM rapid A1c – the world’s first microfluidic-based A1C test.

Eunyoung Park , Engineering Team Director at Orange Biomed, will lead the technical presentations and discussions on the benefits of microfluidics in A1C testing.

“Traditional POC A1C tests also require exact sample sizes to generate accurate results. Patients can struggle to extract the precise amount of blood necessary. Microfluidics enable highly precise, cellular-level analysis, improving the accuracy of results even with inconsistent sample sizes of one drop of blood,” said Park.

“This easier approach could reshape diabetes management and diagnostics in the long term, making effective testing more accessible in everyday healthcare settings and for patients on the go.”

#DiabetesTechnology

#DiabetesTech

#DiabetesTechnologySociety

#A1C

#A1CTesting

#MicrofluidicTechnology

#DiabetesTechnologyMeeting